Unlock valuable biotech data

Sign up for access to the latest biotech data analytic tools and resources

Blog Post

Qualia Bio Announces Acquisition by BluePath Solutions

BluePath Solutions, a leading health economics and value communication consulting firm, has acquired Qualia Bio.


National Average MS-DRG Payment Estimates FY2023 & FY2024

The national average payment for each MS-DRG is calculated by multiplying the fiscal year relative weight of the MS-DRG ...


Clue Cards

Concise summaries of key terms, topics, or policies for subscribers on pharma, biotech, business, and policy.


Our team is known for policy analysis, particularly evidence-based analysis, which we publish as inferences.


Deep dives into topics on pharmaceutical policies, regulations, and economics in biotech


Stay up to date with the latest biotech data analytic news

Tools and Research Tools

We collect, aggregate, curate and enrich medical datasets from various sources. Access these datasets with our research tools to uncover meaningful insights. Then download relevant datasets for further analysis.

Pricescape Tool

A new tool to track prices and price concessions across physician administered drugs, by individual therapies, therapeutic classes, or manufacturers.

Pricescape provides a more complete picture of incomplete data.

PPS Exempt Reconciliation Calculator

Early access

This tool estimates reimbursement for PPS Exempt Cancer Hospitals (PCHs) and details the use of chimeric antigen receptor (CAR) T cell therapies in the economic context

IPPS Grouper & Payment Estimator

Early access

MS-DRG Calculator

Calculate the Base Payments by Provider and Medicare severity diagnosis related group.

SEER Statistics Tool

This tool provides an interface to the Surveillance, Epidemiology, and End Results (SEER) cancer statistics data.

The tool makes it easy to understand which cancers are the most common and how their incidence has changed over time.

Base Payment Estimator

Interact with data published by the Medicare & Medicaid Services (CMS) to quickly estimate Medicare payments for acute care hospital inpatient stays.

This tool helps you easily navigate the complexities of the Inpatient Prospective Payment System (IPPS) rules and weightings that are updated annually.

Solutions and Services

  • Value Based Price Modeling
  • Medicare & Medicaid Reimbursement Estimates
  • Epidemiology Estimates
  • Medicare & Medicaid Learning Modules
  • Hospital Cost & Charge Analytics
  • Proprietary Price-Concession Tools
  • Utilization Management (UM) Analysis
  • Coverage & Reimbursement Risk Analysis
  • Analogue Analysis
  • Geographic Adoption Trends
  • Economic Modeling Courses
  • Epidemiology Estimates
  • Economic Burden Decks
  • Population Funnel Development
  • Patient Geographic Distribution
  • Investigational Device Exemption (IDE) Submissions
  • 513(g) Request for Information Submissions
  • 510(k) (Premarket Notification) Submissions
  • Premarket Approval (PMA) Submissions
  • Orphan Disease Application Support
  • Regulatory & Legal Impact Analysis
  • Pediatric Rare Disease Application Support
  • NTAP Application Support
  • Medicare/Medicaid Learning Modules
  • Risk & Market Evaluations
  • Predicate Determinations
  • Investigational Device Exemption (IDE) Submissions
  • 510(k) (Premarket Notification) Submissions
  • Premarket Approval (PMA) Submissions

Have questions?

Schedule a call with our sales team


Who we work with

About us

Qualia Bio was born out of an idea to help ensure patients' access to innovative and life-saving treatments. To champion said access, we provide insightful political economics and regulatory support for the biotech and finance industries. We're here to help manufacturers or investors monetize a therapy's value attributes, integrate government policies, assess a therapy's potential uptake, or attain a drug class's discount or rebates pressure.

Through our actionable data insights, we make drug acquisitions and market access seamless. We provide resources, apps, and models to as many organizations as possible (not just the biggest companies). We are injecting a necessary step in market access: quick analyses that can be high-level or in-depth, so that your organization can spend resources where they are truly needed.

Read more

Meet the team

View the full team

Ask us to contact you

Preferred contact method
0 / 512


Sign up now with 1 month free trial. Downgrade at anytime.

Free Subscription


  • All Inferences
  • Limited Clue Cards
  • Limited Reports
  • Limited Research tools
Plus Subscription


  • All Inferences
  • All Clue Cards
  • Limited Reports
  • Limited Research tools
Premium Subscription


  • All Inferences
  • All Clue Cards
  • All Reports
  • All Research tools